Autoantibody Response to Islet Transplantation in Type 1 Diabetes

Emanuele Bosi, Simona Braghi, Paola Maffi, Miriam Scirpoli, Federico Bertuzzi, Guido Pozza, Antonio Secchi, Ezio Bonifacio

Research output: Contribution to journalArticle

95 Citations (Scopus)

Abstract

Islet allotransplantation into patients with autoimmune type 1 diabetes represents a reexposure to autoantigen. Here, measurement of antibodies to GAD and IA-2 autoantigens before and after islet transplantation in 36 patients (33 receiving islet plus kidney grafts with cyclosporin and steroid-based immunosuppression, and 3 receiving solitary islet transplants with mycophenolate but cyclosporin-free immunosuppression) demonstrated marked rises in GAD antibodies within 7 days post-transplantation in 5 patients (3 receiving islet after kidney transplants, and 2 receiving solitary islet transplants) and within 30 days in the third patient receiving solitary islet transplantation. GAD antibodies were of the IgG1 subclass, against major autoantigenic epitopes, and in cases of islet after kidney transplants, the responses were short-lived and not accompanied by HLA antibodies. Two of these patients had subsequent marked rises of IA-2 antibodies, and an additional patient had a marked rise in IgM-GAD antibodies 3 years after transplantation. Insulin independence was not achieved in patients with autoantibody elevations and was significantly less frequent in these patients. These data are consistent with a reactivation of autoimmunity that may be dependent on immunosuppression therapy and is associated with impaired graft function.

Original languageEnglish
Pages (from-to)2464-2471
Number of pages8
JournalDiabetes
Volume50
Issue number7-12
Publication statusPublished - Nov 2001

Fingerprint

Islets of Langerhans Transplantation
Type 1 Diabetes Mellitus
Autoantibodies
Transplants
Antibodies
Immunosuppression
Kidney
Cyclosporine
Transplantation
Autoantigens
Autoimmunity
Immunoglobulin M
Epitopes
Immunoglobulin G
Steroids
Insulin

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this

Bosi, E., Braghi, S., Maffi, P., Scirpoli, M., Bertuzzi, F., Pozza, G., ... Bonifacio, E. (2001). Autoantibody Response to Islet Transplantation in Type 1 Diabetes. Diabetes, 50(7-12), 2464-2471.

Autoantibody Response to Islet Transplantation in Type 1 Diabetes. / Bosi, Emanuele; Braghi, Simona; Maffi, Paola; Scirpoli, Miriam; Bertuzzi, Federico; Pozza, Guido; Secchi, Antonio; Bonifacio, Ezio.

In: Diabetes, Vol. 50, No. 7-12, 11.2001, p. 2464-2471.

Research output: Contribution to journalArticle

Bosi, E, Braghi, S, Maffi, P, Scirpoli, M, Bertuzzi, F, Pozza, G, Secchi, A & Bonifacio, E 2001, 'Autoantibody Response to Islet Transplantation in Type 1 Diabetes', Diabetes, vol. 50, no. 7-12, pp. 2464-2471.
Bosi E, Braghi S, Maffi P, Scirpoli M, Bertuzzi F, Pozza G et al. Autoantibody Response to Islet Transplantation in Type 1 Diabetes. Diabetes. 2001 Nov;50(7-12):2464-2471.
Bosi, Emanuele ; Braghi, Simona ; Maffi, Paola ; Scirpoli, Miriam ; Bertuzzi, Federico ; Pozza, Guido ; Secchi, Antonio ; Bonifacio, Ezio. / Autoantibody Response to Islet Transplantation in Type 1 Diabetes. In: Diabetes. 2001 ; Vol. 50, No. 7-12. pp. 2464-2471.
@article{b227ee76559a4ad880b94afd2970cc5a,
title = "Autoantibody Response to Islet Transplantation in Type 1 Diabetes",
abstract = "Islet allotransplantation into patients with autoimmune type 1 diabetes represents a reexposure to autoantigen. Here, measurement of antibodies to GAD and IA-2 autoantigens before and after islet transplantation in 36 patients (33 receiving islet plus kidney grafts with cyclosporin and steroid-based immunosuppression, and 3 receiving solitary islet transplants with mycophenolate but cyclosporin-free immunosuppression) demonstrated marked rises in GAD antibodies within 7 days post-transplantation in 5 patients (3 receiving islet after kidney transplants, and 2 receiving solitary islet transplants) and within 30 days in the third patient receiving solitary islet transplantation. GAD antibodies were of the IgG1 subclass, against major autoantigenic epitopes, and in cases of islet after kidney transplants, the responses were short-lived and not accompanied by HLA antibodies. Two of these patients had subsequent marked rises of IA-2 antibodies, and an additional patient had a marked rise in IgM-GAD antibodies 3 years after transplantation. Insulin independence was not achieved in patients with autoantibody elevations and was significantly less frequent in these patients. These data are consistent with a reactivation of autoimmunity that may be dependent on immunosuppression therapy and is associated with impaired graft function.",
author = "Emanuele Bosi and Simona Braghi and Paola Maffi and Miriam Scirpoli and Federico Bertuzzi and Guido Pozza and Antonio Secchi and Ezio Bonifacio",
year = "2001",
month = "11",
language = "English",
volume = "50",
pages = "2464--2471",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "7-12",

}

TY - JOUR

T1 - Autoantibody Response to Islet Transplantation in Type 1 Diabetes

AU - Bosi, Emanuele

AU - Braghi, Simona

AU - Maffi, Paola

AU - Scirpoli, Miriam

AU - Bertuzzi, Federico

AU - Pozza, Guido

AU - Secchi, Antonio

AU - Bonifacio, Ezio

PY - 2001/11

Y1 - 2001/11

N2 - Islet allotransplantation into patients with autoimmune type 1 diabetes represents a reexposure to autoantigen. Here, measurement of antibodies to GAD and IA-2 autoantigens before and after islet transplantation in 36 patients (33 receiving islet plus kidney grafts with cyclosporin and steroid-based immunosuppression, and 3 receiving solitary islet transplants with mycophenolate but cyclosporin-free immunosuppression) demonstrated marked rises in GAD antibodies within 7 days post-transplantation in 5 patients (3 receiving islet after kidney transplants, and 2 receiving solitary islet transplants) and within 30 days in the third patient receiving solitary islet transplantation. GAD antibodies were of the IgG1 subclass, against major autoantigenic epitopes, and in cases of islet after kidney transplants, the responses were short-lived and not accompanied by HLA antibodies. Two of these patients had subsequent marked rises of IA-2 antibodies, and an additional patient had a marked rise in IgM-GAD antibodies 3 years after transplantation. Insulin independence was not achieved in patients with autoantibody elevations and was significantly less frequent in these patients. These data are consistent with a reactivation of autoimmunity that may be dependent on immunosuppression therapy and is associated with impaired graft function.

AB - Islet allotransplantation into patients with autoimmune type 1 diabetes represents a reexposure to autoantigen. Here, measurement of antibodies to GAD and IA-2 autoantigens before and after islet transplantation in 36 patients (33 receiving islet plus kidney grafts with cyclosporin and steroid-based immunosuppression, and 3 receiving solitary islet transplants with mycophenolate but cyclosporin-free immunosuppression) demonstrated marked rises in GAD antibodies within 7 days post-transplantation in 5 patients (3 receiving islet after kidney transplants, and 2 receiving solitary islet transplants) and within 30 days in the third patient receiving solitary islet transplantation. GAD antibodies were of the IgG1 subclass, against major autoantigenic epitopes, and in cases of islet after kidney transplants, the responses were short-lived and not accompanied by HLA antibodies. Two of these patients had subsequent marked rises of IA-2 antibodies, and an additional patient had a marked rise in IgM-GAD antibodies 3 years after transplantation. Insulin independence was not achieved in patients with autoantibody elevations and was significantly less frequent in these patients. These data are consistent with a reactivation of autoimmunity that may be dependent on immunosuppression therapy and is associated with impaired graft function.

UR - http://www.scopus.com/inward/record.url?scp=0035515764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035515764&partnerID=8YFLogxK

M3 - Article

C2 - 11679423

AN - SCOPUS:0035515764

VL - 50

SP - 2464

EP - 2471

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 7-12

ER -